

Global Thrombocytopenia (Immune & Chemotherapy-induced) Market: Insights, Trends and Forecast (2019-2023)

September 2019

**KONCEPT
ANALYTICS**

Focused, Analytical, Credible

Executive Summary

The global immune thrombocytopenia (ITP) market is expected to reach 2.27 billion in 2023, growing at a CAGR of 5.82%, for the duration spanning 2019-2023. The factors such as, rising healthcare expenditures, growing female population, rising prevalence of arthritis, increasing incidences of hepatitis C and new cases of diagnosed cancer would drive the growth of the market. However, market growth would be challenged by the lethargic drug approval process, side effects associated with available thrombocytopenia drugs and the availability of alternative treatment options. A few notable trends include, novel drug development for thrombocytopenia, increasing number of awareness programs against thrombocytopenia, and increasing preferences for biosimilars.

The global thrombocytopenia market would witness considerable growth in coming years, due to the rising prevalence of thrombocytopenia and associated risk factors. The most common type of thrombocytopenia is ITP, which is highly prevalent in patients with rheumatoid arthritis. Whereas, CIT (Chemotherapy-Induced Thrombocytopenia) occurs in patients with cancer, due to the involvement of chemotherapy and radiation treatment. Thrombocytopenia in patients with CLD is growing rapidly with an increase in incidences of HCV infections among them.

The fastest growing regional market is the U.S., owing to the high prevalence of thrombocytopenia in patients with cancer as well as chronic liver diseases. Moreover, rising awareness about the symptoms and causes of thrombocytopenia among people, through various campaigns and the FDA approvals of various novel drugs for the treatment of thrombocytopenia would drive considerable growth in the global thrombocytopenia market.

Executive Summary

Scope of the report:

- The report provides a comprehensive analysis of the global thrombocytopenia (Immune and Chemotherapy-induced) market.
- The major regional market (the U.S.) has been analyzed.
- The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
- The competitive landscape of the market, along with the company profiles of leading players (Novartis AG, Merck and Co., CSL Limited, Amgen Pharmaceuticals, Horizon Therapeutics and Rigel Pharmaceuticals) are also presented in detail.

Key Target Audience:

- Thrombocytes Drugs Manufacturers
- Chemical Suppliers
- End Users (Hospital, Medical Centers, Clinical Institutes)
- Healthcare Consulting Firms
- Investment Banks
- Government Bodies & Regulating Authorities

Report Coverage

Introduction/Market Overview



Global Market Analysis



Regional Market Analysis



Market Dynamics - Drivers, Trends & Challenges



Competitive Landscape



Company Profiles

Classes of Thrombocytopenia


**Immune
Thrombocytopenic
Purpura (ITP)**

**Chemotherapy-Induced
Thrombocytopenia (CIT)**

The most common type of thrombocytopenia is ITP (Immune Thrombocytopenic Purpura). ITP is highly prevalent in patients with rheumatoid arthritis, because the drugs that are used for the management of rheumatoid arthritis are highly myelosuppressive and reduce the platelet count in a person. Whereas, CIT (Chemotherapy-Induced Thrombocytopenia) occurs in patients with cancer, due to the involvement of chemotherapy and radiation treatment.

Global ITP Market Forecast by Value

Global ITP Market Forecast by Value, 2019-2023 (US\$ billion)




Note: These are dummy figures. Please purchase the report for actual figures.

The global ITP market is projected to record a value of US\$xx billion in 2023, increasing from US\$xx billion in 2019, at a CAGR of xx%, for the duration spanning 2019-2023. Certain factors such as, rising female population, rising prevalence of arthritis and increasing healthcare expenditures would propel the growth of the market.

Global ITP Total Patient Volume Forecast

Global ITP Total Patient Volume Forecast, 2019-2023 (Thousand)




Note: These are dummy figures. Please purchase the report for actual figures.

The global ITP total patients volume is expected to reach xx thousand patients in 2023, increasing from xx thousand patients in 2019, at a CAGR of xx%, during 2019-2023. The major factor for the rising prevalence of thrombocytopenia would be the high occurrence of its associated risk factors such as prognosis, HIV, hepatitis C, etc.

Global ITP Total Patient Volume Forecast by Region

Global ITP Total Patient Volume Forecast by Region , 2023 (%)




Note: These are dummy figures. Please purchase the report for actual figures.

The global ITP total patient volume is likely to be segmented into the U.S. and ROW. In 2023, the U.S. is expected to hold xx% share in the global ITP total patient volume. While, ROW is projected to account for xx% share.

Global ITP Treated Patient Volume Forecast

Global ITP Treated Patient Volume Forecast, 2019-2023 (Thousand)




Note: These are dummy figures. Please purchase the report for actual figures.

Out of the total ITP patient volume, xx thousand patients are expected to receive treatment in 2023, increasing from xx thousand patients in 2019, at a CAGR of xx%, during 2019-2023. Rising preferences for biosimilars would also contribute to the increase in ITP treated patient volume across the world.

Global CIT Total Patient Volume Forecast

Global CIT Total Patient Volume Forecast, 2018-2023 (Million)




Note: These are dummy figures. Please purchase the report for actual figures.

In 2018, xx million patients experienced CIT. The CIT total patient volume is further expected to reach xx million patients in 2023, as compared to xx million patients in 2019, growing at a CAGR of xx% for the time period of 2018-2023. The prevalence of CIT would increase due to the increase in number of new diagnosed cases of cancer across the world.

Global CIT Total Patient Volume Forecast by Region

Global CIT Total Patient Volume Forecast by Region, 2018/2023 (%)




Note: These are dummy figures. Please purchase the report for actual figures.

In 2018, the U.S. accounted for xx% share in the global CIT total patient volume forecast, followed by ROW with xx% share. The U.S. would continue to hold significant share in the CIT patient population in coming years. In 2023, the U.S. is likely to hold xx% share of the global CIT total patient volume, whereas, ROW is projected to accounted for xx% share.

Global CIT Treated Patient Volume Forecast

Global CIT Treated Patient Volume Forecast, 2018-2023 (Thousand)



Note: These are dummy figures. Please purchase the report for actual figures.

Out of the total CIT patient volume, xx thousand patients received treatment in 2018. The CIT treated patient volume is further expected to reach xx thousand patients in 2023, increasing from xx thousand patients in 2019, at a CAGR of xx%, during 2018-2023. The rising preference for blood or platelet transfusion would promote the increase in number of treated CIT patient across the world.

Disclaimer

This is a licensed product of Konzept Analytics. You cannot reproduce, publish, distribute, publicly display, sell or create other works from this report or use them in any way for commercial purpose without our prior permission. Further, you cannot copy this material, by any means (including electronic copies), for distribution to others unless you have purchased the corporate license of this report.

We believe the sources are reliable, but Konzept Analytics does not warranty the accuracy or completeness of the data. The data presented in the report is updated at the publication date but is subject to change at subsequent releases. All possible efforts have been made to ensure accuracy of data. However, investors should not completely rely on the information given in this report and must make decisions based on their own investment strategy, risk management and capital adequacy.

Konzept Analytics
CS-36, First Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. - 201010
T: +91-120-4130959
M: +91-8826830618
vikas@konceptanalytics.com

www.konceptanalytics.com